Jaundice (Icterus) - Causes, Treatment & When to See a Doctor

What is Jaundice (Icterus)?

Jaundice, medically known as icterus, is a yellowish discoloration of the skin, sclerae (the whites of the eyes), and mucous membranes caused by an excess of bilirubin in the bloodstream. Bilirubin is a yellow pigment produced during the normal breakdown of red blood cells. When the liver cannot process or excrete bilirubin efficiently, it accumulates, leading to the characteristic color change.

While a mild, temporary rise in bilirubin is common in newborns, persistent jaundice in children or adults usually signals an underlying health problem that warrants evaluation.

Common Causes

Jaundice can result from a wide range of conditions that affect bilirubin production, transport, metabolism, or excretion. The most frequent causes fall into three categories: pre‑hepatic (before the liver), hepatic (within the liver), and post‑hepatic (after the liver). Below are 10 common conditions that can lead to icterus.

• Hemolytic anemia – accelerated destruction of red blood cells (e.g., sickle‑cell disease, autoimmune hemolysis) increases bilirubin production.
• Viral hepatitis – inflammation of liver cells (A, B, C, D, E) impairs bilirubin processing.
• Alcoholic liver disease – chronic alcohol use damages hepatocytes and reduces bilirubin clearance.
• Non‑alcoholic fatty liver disease (NAFLD) – fat accumulation in the liver can progress to steatohepatitis and cirrhosis.
• Biliary obstruction – gallstones, strictures, or tumors block the bile ducts, preventing bilirubin excretion.
• Primary sclerosing cholangitis (PSC) – chronic inflammation and scarring of the bile ducts.
• Pancreatic cancer (head of pancreas) – can compress the common bile duct, causing obstructive jaundice.
• Gilbert’s syndrome – a benign genetic defect in bilirubin conjugation that causes intermittent mild jaundice.
• Drug‑induced liver injury – acetaminophen overdose, certain antibiotics, or herbal supplements can damage hepatocytes.
• Neonatal physiologic jaundice – immature liver enzymes in newborns lead to temporary bilirubin rise (usually resolves within 2 weeks).

Associated Symptoms

Jaundice rarely occurs in isolation. The following symptoms often accompany icterus, depending on the underlying cause:

• Dark urine (bilirubin‑colored) and pale, clay‑colored stools
• Pruritus (itchy skin) – especially in cholestatic (bile‑flow) disorders
• Abdominal pain or fullness, particularly in the right upper quadrant
• Fatigue, weakness, or malaise
• Unexplained weight loss
• Fever or chills (suggesting infection such as cholangitis)
• Bruising or easy bleeding (if liver synthetic function is impaired)
• Swelling of the abdomen (ascites) or legs (edema)
• Confusion, personality changes, or a “flapping” tremor (asterixis) – signs of hepatic encephalopathy

When to See a Doctor

Because jaundice can signal serious disease, prompt medical attention is essential when any of the following occur:

• Yellowing of the eyes or skin that persists longer than 2–3 days.
• Severe abdominal pain, especially in the upper right quadrant.
• Fever > 38 °C (100.4 °F) accompanied by chills.
• Dark urine or pale stools that do not improve.
• Unexplained weight loss, loss of appetite, or persistent nausea/vomiting.
• Signs of bleeding (easy bruising, nosebleeds, blood in stool).
• Confusion, drowsiness, or difficulty concentrating.
• Newborns with yellowing that spreads to the torso, lasts > 2 weeks, or is accompanied by poor feeding or lethargy.

Early evaluation helps identify life‑threatening conditions such as biliary obstruction, severe hepatitis, or hemolytic crises.

Diagnosis

Diagnosing jaundice involves confirming elevated bilirubin levels and pinpointing the cause. The typical work‑up includes:

1. Laboratory Tests

• Total and direct (conjugated) bilirubin – distinguishes between pre‑hepatic (unconjugated) and hepatic/post‑hepatic (conjugated) jaundice.
• Liver function panel – AST, ALT, alkaline phosphatase (ALP), gamma‑glutamyl transferase (GGT), and albumin.
• Complete blood count (CBC) – looks for anemia, infection, or leukocytosis.
• Hemolysis work‑up – haptoglobin, lactate dehydrogenase (LDH), reticulocyte count, and peripheral smear.
• Viral hepatitis serologies – hepatitis A IgM, hepatitis B surface antigen/antibody, hepatitis C antibody.
• Autoimmune markers – ANA, anti‑smooth muscle, anti‑mitochondrial antibodies if autoimmune hepatitis is suspected.

2. Imaging Studies

• Abdominal ultrasound – first‑line to assess gallstones, bile duct dilation, liver size, and vascular flow.
• CT or MRI – provides detailed anatomy for tumors, strictures, or pancreatic lesions.
• Magnetic resonance cholangiopancreatography (MRCP) – non‑invasive visualization of the biliary tree.
• Endoscopic retrograde cholangiopancreatography (ERCP) – diagnostic and therapeutic (e.g., stone removal, stent placement).

3. Specialized Tests

• Liver biopsy – reserved for unclear cases where histology will change management (e.g., distinguishing NASH from autoimmune hepatitis).
• Genetic testing – for hereditary conditions such as Gilbert’s syndrome or Crigler‑Najjar.

Treatment Options

Treatment is directed at the underlying cause and at relieving symptoms. Below are the main therapeutic pathways.

1. Addressing the Root Cause

• Hemolysis – stop offending drugs, treat autoimmune hemolysis with steroids or immunosuppressants, transfuse red cells if needed.
• Viral hepatitis – antiviral agents (e.g., sofosbuvir/velpatasvir for HCV, entecavir or tenofovir for HBV) and supportive care.
• Alcoholic liver disease – complete abstinence, nutritional support, and possibly corticosteroids for severe alcoholic hepatitis.
• Biliary obstruction – endoscopic stone extraction, stent placement, or surgical removal of tumors/strictures.
• NAFLD/NASH – weight loss (7–10 % of body weight), exercise, control of diabetes and hyperlipidemia, and emerging pharmacotherapies (e.g., obeticholic acid).
• Drug‑induced injury – immediate cessation of the offending agent; N‑acetylcysteine for acetaminophen toxicity.

2. Symptom‑Focused Care

• Pruritus – cholestyramine, rifampin, or antihistamines; in refractory cases, bile‑acid sequestrants or opioid antagonists (naltrexone).
• Phototherapy – the mainstay for significant neonatal jaundice; blue‑light converts bilirubin into water‑soluble forms.
• Intravenous fluids – maintain hydration, especially in hemolytic crises or cholestatic disease.
• Nutritional support – high‑calorie, high‑protein diet; vitamin K supplementation if coagulopathy is present.

3. Home & Lifestyle Measures

• Stay well‑hydrated (aim for ≥ 2 L water/day unless contraindicated).
• Limit alcohol and avoid hepatotoxic over‑the‑counter medications (e.g., high‑dose acetaminophen).
• Adopt a balanced diet rich in fruits, vegetables, whole grains, and lean protein.
• Maintain a healthy weight; gradual weight loss improves NAFLD‑related jaundice.

Prevention Tips

While some causes (genetic disorders, certain cancers) cannot be prevented, many risk factors are modifiable:

• Vaccinate against hepatitis A and B.
• Practice safe sex and avoid sharing needles to reduce hepatitis C transmission.
• Limit alcohol intake – no more than 1 drink per day for women and 2 for men.
Maintain a healthy weight – BMI < 25 kg/m² lowers NAFLD risk.
• Use medications responsibly – follow dosing guidelines, avoid unnecessary herbal supplements.
• Regular health screenings – liver function tests for people with diabetes, obesity, or a family history of liver disease.
• Prompt treatment of infections – urinary or biliary infections can precipitate cholestasis.

Emergency Warning Signs

References

• Mayo Clinic. “Jaundice.” https://www.mayoclinic.org. Accessed 2024.
• National Institutes of Health (NIH). “Bilirubin Metabolism.” https://www.ncbi.nlm.nih.gov. 2023.
• Centers for Disease Control and Prevention (CDC). “Hepatitis A, B, and C.” https://www.cdc.gov. Updated 2024.
• Cleveland Clinic. “Jaundice: Causes, Symptoms, and Treatment.” https://my.clevelandclinic.org. 2024.
• World Health Organization (WHO). “Non‑communicable diseases: Liver disease.” https://www.who.int. 2023.
• American College of Gastroenterology. “Guidelines for the Management of Biliary Tract Disease.” Gastroenterology, 2022.